What question did this study set out to answer?

This study aims to assess the use and feasibility of Indocyanine Green (ICG) as a tracer in sentinel lymph node biopsy for breast cancer in India.

March 25, 2026CancersOpen Access

Evaluating the Use and Feasibility of Indocyanine Green (ICG) as a Beacon of Precision in Sentinel Node Biopsy for Breast Cancer from an Oncoplastic Practice in India

View Full Paper

Ask AI

Bookmark

Authors

Evaluates the efficacy of indocyanine green in sentinel node biopsy for breast cancer, suggesting its practical use in low-resource settings.

This study aims to assess the use and feasibility of Indocyanine Green (ICG) as a tracer in sentinel lymph node biopsy for breast cancer in India.
Analyzed data from 678 breast cancer patients between 2013–2023.
Grouped patients into control (isotope + blue dye), study (ICG + blue dye), and ICG alone.
Evaluated false-negative rate and other outcomes across the sentinel lymph node biopsy cohort.
Study group had 95.6% identification rate and 5% false-negative rate in upfront surgery.
Post-neoadjuvant systemic therapy, study group outperformed control with 92% identification rate.
ICG alone achieved 100% identification rate and 0% false-negative rate in upfront cases.

Koppiker et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Evaluates the efficacy of indocyanine green in sentinel node biopsy for breast cancer, suggesting its practical use in low-resource settings.